Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry

Clinical Rheumatology

Volumn 36, Issue 4, 2017, Pages 753-761

  Monti, Sara ^a   Klersy, Catherine ^b   Gorla, Roberto ^c   Sarzi Puttini, Piercarlo ^d   Atzeni, Fabiola ^d   Pellerito, Raffaele ^e   Fusaro, Enrico ^f   Paolazzi, Giuseppe ^g   Rocchetta, Pier Andrea ^h   Favalli, Ennio Giulio ⁱ   Marchesoni, Antonio ⁱ   Caporali, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c SPEDALI CIVILI   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e MAURIZIANO HOSPITAL   (Italy)

^f CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^g SANTA CHIARA HOSPITAL   (Italy)

^h SS Antonio e Biagio e Cesare Arrigo Hospital   (Italy)

ⁱ ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Abatacept; Biologic therapy; Rheumatoid arthritis; TNF inhibitors; Tocilizumab; Treatment choice

Indexed keywords

ABATACEPT; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; LATENT TUBERCULOSIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; RHEUMATOID VASCULITIS; RISK FACTOR; SCREENING; SCREENING TEST; ADVERSE EFFECTS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; ITALY; PROCEDURES; REGISTER; STATISTICAL MODEL;

ABATACEPT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ITALY; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85008428237     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-016-3528-y     Document Type: Article

References (36)

1. Nam JL, Ramiro S, Gaujoux-Viala C et al (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516–528
2. Schiff M, Weinblatt ME, Valente R et al (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73:86–94
3. Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T (2013) Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Jt Bone Spine Rev Rhum 80:386–392
4. Favalli EG, Bugatti S, Biggioggero M, Caporali R (2014) Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int 2014:831603
5. Jobanputra P, Maggs F, Deeming A, et al. (2012) A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2(6)
6. Gabay C, Emery P, van Vollenhoven R et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877):1541–1550
7. Smolen JS, Landewé R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509
8. Caporali R, Sarzi-Puttini P, Atzeni F et al (2010) Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 9:465–469
9. Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol
10. Tanaka Y, Kubo S, Yamanaka H et al (2014) Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia® as Biological Intensive Treatment for RA (ORBIT) study. Mod Rheumatol 24:754–762
11. Yun H, Xie F, Delzell E, Levitan EB et al (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol Hoboken NJ 68:56–66
12. Cantini F, Niccoli L, Nannini C, et al. (2015) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum
13. Sarzi-Puttini P, Antivalle M, Marchesoni A et al (2008) Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60:290–295
14. van den Broek M, Lems WF, Allaart CF (2012) Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 30(4 Suppl 73):S21–S26
15. Tanaka Y, Hirata S (2013) Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Clin Ther 35:2028–2035
16. Moghadam MG, Vonkeman HE, Ten Klooster PM, et al. (2016) Stopping tumor necrosis factor-inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open-label controlled trial. Arthritis Rheumatol Hoboken NJ
17. Radovits BJ, Fransen J, Eijsbouts A, van Riel PLCM, Laan RFJM (2009) Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology 48:906–910
18. Morsley K, Kilner T, Steuer A (2015) Biologics prescribing for rheumatoid arthritis in older patients: a single-center retrospective cross-sectional study. Rheumatol Ther 2:165–172
19. Martin WJ, Shim M, Paulus HE et al (2014) Older age at rheumatoid arthritis onset and comorbidities correlate with less health assessment questionnaire-disability index and clinical disease activity index response to etanercept in the RADIUS 2 registry. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 20:301–305
20. Sugihara T, Harigai M (2016) Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging 33:97–107
21. Zhang J, Xie F, Yun H, et al. (2016) Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis
22. Crepaldi G, Scirè CA, Carrara G et al (2016) Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis. PLoS One 11:e0146991
23. Kroot EJ, van Gestel AM, Swinkels HL, Albers MM, van de Putte LB, van Riel PL (2001) Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol 28:1511–1517
24. Innala L, Sjöberg C, Möller B et al (2016) Co-morbidity in patients with early rheumatoid arthritis - inflammation matters. Arthritis Res Ther 18:33
25. Dougados M, Soubrier M, Antunez A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73:62–68
26. Iqbal K, Kelly C (2015) Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 7:247–267
27. Cavagna L, Monti S, Grosso V et al (2013) The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013:759760
28. Marino S, Sud D, Plessner H, et al. (2007) Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol [Internet] 3(10)
29. Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese MC (2014) Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol Hoboken NJ 66:1987–1997
30. Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103
31. Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25–32
32. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96
33. Buckley F, Finckh A, Huizinga TWJ, Dejonckheere F, Jansen JP (2015) Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm 21:409–423
34. Gabay C, Riek M, Hetland ML, et al. (2015) Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis
35. Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatol Oxf Engl 53:1664–1668
36. Lee YH, Bae S-C (2015) Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis